Correction: Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets (Annals of Internal Medicine (2017) 166 (430-437) DOI: 10.7326/M16-1785);Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians

Annals of Internal Medicine

Volumn 166, Issue 6, 2017, Pages 430-437

  Qaseem, Amir ^a   Wilt, Timothy J ^b   Rich, Robert ^c   Humphrey, Linda L ^d   Frost, Jennifer ^e   Forciea, Mary Ann ^f  

^a AMERICAN COLLEGE OF PHYSICIANS   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Bladen Medical   (United States)

^d VETERANS AFFAIRS PORTLAND HEALTH CARE SYSTEM   (United States)

^e AMERICAN ACADEMY OF FAMILY PHYSICIANS   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

AGE; ALL CAUSE MORTALITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; DIASTOLIC BLOOD PRESSURE; EVIDENCE BASED MEDICINE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR ADVERSE CARDIAC EVENT; MEDICAL HISTORY; MORBIDITY; MULTIPLE CHRONIC CONDITIONS; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SUDDEN CARDIAC DEATH; SYSTEMATIC REVIEW (TOPIC); SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; CARDIOVASCULAR DISEASES; COMORBIDITY; RISK ASSESSMENT; SECONDARY PREVENTION; STROKE;

AGE FACTORS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; HUMANS; HYPERTENSION; RISK ASSESSMENT; SECONDARY PREVENTION; STROKE;

EID: 85013233576     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/L18-0076     Document Type: Erratum

References (50)

1. Yoon SS, Fryar CD, Carroll MD. Hypertension Prevalence and Control among Adults: United States, 2011-2014. NCHS Data Brief no. 220. Hyattsville, MD: National Center for Health Statistics; 2015.
2. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics- 2015 update: A report from the American Heart Association. Circulation. 2015; 131: E29-322. [PMID: 25520374] doi: 10.1161/CIR.000 0000000000152
3. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967; 202: 1028-34. [PMID: 4862069]
4. Medical Research Council trial of treatment of hypertension in older adults: Principal results. MRC Working Party. BMJ. 1992; 304: 405-12. [PMID: 1445513]
5. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970; 213: 1143-52. [PMID: 4914579]
6. The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet. 1980; 1: 1261-7. [PMID: 6104081]
7. James PA, Oparil S, Carter BL, Cushman WC, Dennison- Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311: 507-20. [PMID: 24352797] doi: 10.1001 /jama.2013.284427
8. Weiss J, Freeman M, Low A, Fu R, Kerfoot A, Paynter R, et al. Benefits and harms of intensive blood pressure treatment in adults aged 60 years or older. A systematic review and meta-analysis. Ann Intern Med. 2017; 166: 419-29. doi: 10.7326/M16-1754
9. Weiss J, Kerfoot A, Freeman M, Motu'apuaka M, Fu R, Low A, et al. Benefits and Harms of Treating Blood Pressure in Older Adults: A Systematic Review and Meta-analysis. VA ESP project no. 05-225. Washington, DC: U.S. Department of Veterans Affairs; 2015.
10. Qaseem A, Snow V, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. The development of clinical practice guidelines and guidance statements of the American College of Physicians: Summary of methods. Ann Intern Med. 2010; 153: 194-9. [PMID: 20679562] doi: 10.7326/0003-4819 -153-3-201008030-00010
11. Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, et al; Cardio-Sis investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): An open-label randomised trial. Lancet. 2009; 374: 525-33. [PMID: 19683638] doi: 10.1016/S0140-6736(09)61340-4
12. Hansson L, Zanchetti A, Carruthers SG, Dahlö f B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and lowdose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351: 1755-62. [PMID: 9635947]
13. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008; 31: 2115-27. [PMID: 19139601] doi: 10.1291/hypres.31.2115
14. Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med. 2000; 160: 211-20. [PMID: 10647760]
15. Amery A, Birkenhä ger W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985; 1: 1349-54. [PMID: 2861311]
16. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358: 1887-98. [PMID: 18378519] doi: 10.1056/NEJMoa0801369
17. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens. 2003; 21: 875-86. [PMID: 12714861]
18. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991; 265: 3255-64. [PMID: 2046107]
19. Hara A, Thijs L, Asayama K, Jacobs L, Wang JG, Staessen JA. Randomised double-blind comparison of placebo and active drugs for effects on risks associated with blood pressure variability in the Systolic Hypertension in Europe trial. PLoS One. 2014; 9: E103169. [PMID: 25090617] doi: 10.1371/journal.pone.0103169
20. Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, et al; Valsartan in Elderly Isolated Systolic Hypertension Study Group. Target blood pressure for treatment of isolated systolic hypertension in the elderly: Valsartan in elderly isolated systolic hypertension study. Hypertension. 2010; 56: 196-202. [PMID: 20530299] doi: 10.1161/HYPERTENSIONAHA.109.146035
21. Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Pagé V, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens. 1996; 14: 1237-45. [PMID: 8906524]
22. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al; ACCORD Study Group. Effects of intensive bloodpressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362: 1575-85. [PMID: 20228401] doi: 10.1056/NEJMoa1001286
23. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373: 2103-16. [PMID: 26551272] doi: 10.1056/NEJMoa1511939
24. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet. 2007; 370: 829-40. [PMID: 17765963]
25. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A; FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: A randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005; 23: 2157-72. [PMID: 16269957]
26. White CL, Szychowski JM, Pergola PE, Field TS, Talbert R, Lau H, et al; Secondary Prevention of Small Subcortical Strokes Study Investigators. Can blood pressure be lowered safely in older adults with lacunar stroke? The Secondary Prevention of Small Subcortical Strokes study experience. J Am Geriatr Soc. 2015; 63: 722-9. [PMID: 25850462] doi: 10.1111/jgs.13349
27. PROGRESS Collaborative Group. Randomised trial of a perindoprilbased blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358: 1033-41. [PMID: 11589932]
28. Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, et al; SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: The SPS3 randomised trial. Lancet. 2013; 382: 507-15. [PMID: 23726159] doi: 10.1016/S0140-6736(13) 60852-1
29. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al; Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. Lancet. 2008; 372: 1174-83. [PMID: 18757085] doi: 10.1016/S0140-6736(08)61242-8
30. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al; SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged =75 years: A randomized clinical trial. JAMA. 2016; 315: 2673-82. [PMID: 27195814] doi: 10.1001/jama.2016.7050
31. Ruggenenti P, Fassi A, Ilieva A, Iliev IP, Chiurchiu C, Rubis N, et al; BENEDICT-B Study Investigators. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: The BENEDICT-B randomized trial. J Hypertens. 2011; 29: 207-16. [PMID: 21243736]
32. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861-9. [PMID: 11565518]
33. Voyaki SM, Staessen JA, Thijs L, Wang JG, Efstratopoulos AD, Birkenhä ger WH, et al; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. J Hypertens. 2001; 19: 511-9. [PMID: 11288822]
34. Peralta CA, McClure LA, Scherzer R, Odden MC, White CL, Shlipak M, et al. Effect of intensive versus usual blood pressure control on kidney function among individuals with prior lacunar stroke: A post hoc analysis of the Secondary Prevention of Small Subcortical Strokes (SPS3) randomized trial. Circulation. 2016; 133: 584-91. [PMID: 26762524] doi: 10.1161/CIRCULATIONAHA.115.019657
35. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, et al; HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): A double-blind, placebo controlled trial. Lancet Neurol. 2008; 7: 683-9. [PMID: 18614402] doi: 10.1016 /S1474-4422(08)70143-1
36. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al; Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: New evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002; 162: 2046-52. [PMID: 12374512]
37. Williamson JD, Launer LJ, Bryan RN, Coker LH, Lazar RM, Gerstein HC, et al; Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: A randomized clinical trial. JAMA Intern Med. 2014; 174: 324-33. [PMID: 24493100] doi: 10 .1001/jamainternmed.2013.13656
38. Skoog I, Lithell H, Hansson L, Elmfeldt D, Hofman A, Olofsson B, et al; SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Am J Hypertens. 2005; 18: 1052-9. [PMID: 16109319]
39. Bird AS, Blizard RA, Mann AH. Treating hypertension in the older person: An evaluation of the association of blood pressure level and its reduction with cognitive performance. J Hypertens. 1990; 8: 147-52. [PMID: 2162877]
40. Margolis KL, Palermo L, Vittinghoff E, Evans GW, Atkinson HH, Hamilton BP, et al. Intensive blood pressure control, falls, and fractures in patients with type 2 diabetes: The ACCORD trial. J Gen Intern Med. 2014; 29: 1599-606. [PMID: 25127725] doi: 10.1007/s11606 -014-2961-3
41. Peters R, Beckett N, Burch L, de Vernejoul MC, Liu L, Duggan J, et al. The effect of treatment based on a diuretic (indapamide) ? ACE inhibitor (perindopril) on fractures in the Hypertension in the Very Elderly Trial (HYVET). Age Ageing. 2010; 39: 609-16. [PMID: 20573778] doi: 10.1093/ageing/afq071
42. Applegate WB, Pressel S, Wittes J, Luhr J, Shekelle RB, Camel GH, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med. 1994; 154: 2154-60. [PMID: 7944835]
43. Fletcher AE, Bulpitt CJ, Thijs L, Tuomilehto J, Antikainen R, Bossini A, et al; Syst-Eur Trial Investigators. Quality of life on randomized treatment for isolated systolic hypertension: Results from the Syst-Eur Trial. J Hypertens. 2002; 20: 2069-79. [PMID: 12359987]
44. Wiklund I, Halling K, Rydé n-Bergsten T, Fletcher A. Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study. Blood Press. 1997; 6: 357-64. [PMID: 9495661]
45. Siu AL; U.S. Preventive Services Task Force. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015; 163: 778-86. [PMID: 26458123] doi: 10.7326/M15-2223
46. Choudhry NK, Denberg TD, Qaseem A; Clinical Guidelines Committee of American College of Physicians. Improving adherence to therapy and clinical outcomes while containing costs: Opportunities from the greater use of generic medications: Best practice advice from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2016; 164: 41-9. [PMID: 26594818] doi: 10.7326/M14-2427
47. Nuesch R, Schroeder K, Dieterle T, Martina B, Battegay E. Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: A prospective case-control study. BMJ. 2001; 323: 142-6. [PMID: 11463685]
48. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990; 150: 1881-4. [PMID: 2102668]
49. Higgins JPT, Green S, eds. Assessing risk of bias in included studies. In: Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1. The Cochrane Collaboration. 2008. Accessed at http: //handbook.cochrane.org on 21 December 2016.
50. Berkman ND, Lohr KN, Ansari M, McDonagh M, Balk E, Whitlock E, et al. AHRQ Methods for Effective Health Care Grading the Strength of a Body of Evidence When Assessing Health Care Interventions for the Effective Health Care Program of the Agency for Healthcare Research and Quality: An Update. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville: Agency for Healthcare Research and Quality; 2008.